首页> 外文期刊>Hematology/Oncology and Stem Cell Therapy >What is the place of hematopoietic stem cell transplantation in the management of cerebral vasculopathy in children with sickle cell anemia?
【24h】

What is the place of hematopoietic stem cell transplantation in the management of cerebral vasculopathy in children with sickle cell anemia?

机译:患有镰状细胞贫血儿童脑血管病理脑血管病理中的造血干细胞移植的地方是什么?

获取原文
           

摘要

Cerebral vasculopathy is the most severe complication affecting children with sickle cell anemia. Significant progress has been made in the management of sickle cell anemia cerebral vasculopathy, including early transcranial Doppler screening, chronic transfusion, andhydroxyurea. Nevertheless, for patients with a potential matched-sibling donor (MSD), stem cell transplantation (SCT) is now the treatment offering the best cerebral vasculopathy outcome. In the absence of MSD,alternative SCT should be recommended only in those with worsening cerebral vasculopathy despite standard treatments, and should be limited to related haplo-identical SCT undertaken in controlled studies.Copyright ? 2020. Published by Elsevier Ltd.
机译:脑血管病是影响镰状细胞贫血儿童的最严重的并发症。在镰状细胞贫血脑血管病变管理中取得了重大进展,包括早期经颅多普勒筛查,慢性输血,羟基脲。然而,对于潜在的匹配兄弟供体(MSD)的患者,干细胞移植(SCT)现在是提供最佳脑血管病变的治疗。在没有MSD的情况下,尽管标准治疗尽管存在脑血管病变,但应在那些中建议替代SCT,并且应限于在受控研究中进行的相关的HPLO相同SCT .Copyright? 2020年由elestvier有限公司出版

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号